Delivering clinical supplies into the European Union and United Kingdom requires rigorous
oversight from a QP to ensure every batch meets regulatory, GMP, and trial-specific requirements. Yet, many
sponsors face preventable delays, often due to incomplete documentation, limited supply chain visibility, or
late communication of changes. This paper breaks down the core responsibilities of the QP, explains how
European Union and United Kingdom expectations differ, and share practical steps sponsors can take to
streamline the certification process. Readers will learn how to prepare audit-ready documentation, avoid
common pitfalls that extend release timelines, and build efficient collaborations with QPs to keep studies
moving without interruption.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.